SCHEMBL20725848

SCHEMBL20725848

Cc1cc2cc[nH]c(=O)c2cc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ROCK2 O75116 8/20 0.43
JAK2 O60674 1/20 0.43
RPS6KA3 P51812 1/20 0.43
MELK Q14680 1/20 0.43
STK24 Q9Y6E0 1/20 0.43
ROCK1 Q13464 2/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
GRM5 P41594 1/20 0.41
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
INCENP Q9NQS7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324485 0.93 ROCK1 (0.45) PARP1RECQLTDP1ROCK2JAK2
SCHEMBL17321356 0.85 PARP1 (0.50) PARP1ROCK2ROCK1KDM4EALDH1A1
SCHEMBL22473866 0.82 PARP1 (0.44) PARP1ROCK2ROCK1GRM5CHEK1
SCHEMBL12448944 0.79 ROCK2 (0.57) PARP1ROCK2ROCK1
SCHEMBL12034618 0.79 PARP1 (0.44) PARP1ROCK2ROCK1KDM4EALDH1A1
SCHEMBL4002310 0.79 TYMS (0.50) PARP1RECQLTDP1ROCK2JAK2
SCHEMBL17801551 0.79 PARP1 (0.44) PARP1RECQLTDP1ROCK2JAK2
Hydrochloric Acid SCHEMBL4002322 0.77 TYMS (0.49) PARP1RECQLTDP1ROCK2JAK2
SCHEMBL4000783 0.75 ROCK2 (0.54) PARP1RECQLTDP1ROCK2ROCK1
SCHEMBL4008761 0.75 ROCK2 (0.47) PARP1ROCK2ROCK1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227279-B1 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS LILLY CO ELI (US) 2019-02-13 EP disclosed